Claritas Genomics: 2015 Highlights
A year of significant advances to improve rare disease diagnosis in children
A year of significant advances to improve rare disease diagnosis in children
CAMBRIDGE, Mass., Jan. 21, 2016 /PRNewswire-USNewswire/ -- 2015 was a year of advances for Claritas Genomics continuing the company's mission to advance precision care for children. The company secured $15 million for its Series B, launched new diagnostic gene tests, announced a partnership with the world's largest rare disease patient advocacy organization, sequenced 19,600 research exomes, announced its Scientific Advisory Board and became one of only eight clinical laboratories in the US to be awarded the International Standardization Organization's (ISO) 15189 accreditation by the American Association for Laboratory Accreditation (A2LA). In 2015, Claritas:
About Claritas Genomics
Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families' long search for answers. By combining clinical expertise of the world's best pediatric specialists with innovative platform solutions, Claritas is working to improve patient care and enable new discoveries.
For more information about Claritas Genomics, visit www.claritasgenomics.com
Contact:
Betsy Stevenson
Director of Corporate Communications
[email protected]
Tel: (860) 984-1424
Logo - http://photos.prnewswire.com/prnh/20150123/171145LOGO
SOURCE Claritas Genomics
Share this article